PharmAbcine Inc.

Equities

A208340

KR7208340000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 04:30:00 19/01/2024 am IST			5-day change	1st Jan Change
2,915 ^KRW	-8.91%		-.--%	-22.27%

14/06	PharmAbcine Inc. announced that it expects to receive KRW 3.7117955 billion in funding	CI
24/01	PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	CI

PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc.

December 01, 2023

On December 1, 2023, PharmAbcine Inc. closed the transaction. The transaction will include participation from new investors Hpbiolab Inc. for 5,336,179 shares and Seung-hwan Choi for 5,336,180 shares.

Latest news about PharmAbcine Inc.

PharmAbcine Inc. announced that it expects to receive KRW 3.7117955 billion in funding	14/06	CI
PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	24/01	CI
PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	26/12	CI
PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc.	01/12	CI
Pharmabcine, Inc. Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-Related Macular Degeneration Following Dose Level 1 Safety Data	09/11	CI
PharmAbcine Inc. announced that it expects to receive KRW 5.000000492 billion in funding	26/23/26	CI
PharmAbcine Inc. announced extension to the offering period	07/23/07	CI
Yukon Partners Co., Ltd. acquired a 6.2% stake in PharmAbcine Inc. from Yoo Jin San for KRW 4.4 billion	27/23/27	CI
PharmAbcine Inc. announced that it expects to receive KRW 30.000001149 billion in funding	16/23/16	CI
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of its Novel TIE2 Agonistic Antibody in nAMD	23/23/23	CI
PharmAbcine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI
Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab)	12/22/12	CI
PharmAbcine Inc.(KOSDAQ:A208340) dropped from S&P Global BMI Index	19/22/19	CI
Pharmabcine Inc. Announces the Positive Results from the GLP Toxicology Study of PMC-403, the Company's Novel TIE2-Activating Antibody	26/22/26	CI
PharmAbcine Inc. Announces the Appointment of Quan Dong Nguyen to its Scientific Advisory Board	26/22/26	CI
PharmAbcine Inc. announced that it has received KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm	15/22/15	CI
PharmAbcine Inc. announced that it expects to receive KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm and other investors	13/22/13	CI
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022	11/22/11	CI
RNAGene Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel Mrna Therapeutics	21/22/21	CI
NuclixBio Inc. Announces a Collaborative Research Agreement with PharmAbcine Inc	14/22/14	CI
PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022	09/22/09	CI
PharmAbcine Inc. Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial	25/22/25	CI
PharmAbcine Inc. Announces First Patient Enrolled and Dosed in the Phase Ii Clinical Trial for the Treatment of mTNBC	27/21/27	CI
PharmAbcine, Inc. Announces Joint Patent Application with MSD for the Treatment of Cancer	09/21/09	CI
PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC	03/21/03	CI

Chart PharmAbcine Inc.

Duration

Period

More charts

Company Profile

PharmAbcine Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Companyâs major products include tanibirumab used for cancer treatment, among others. The Company also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMABCINE INC.	-22.27%	63.48M
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
REGENERON PHARMACEUTICALS, INC.	+19.65%	113B
ARGENX SE	+21.22%	26.49B
BIONTECH SE	-23.84%	19.4B
GENMAB A/S	-17.47%	16.24B
WUXI APPTEC CO., LTD.	-45.95%	15.15B
BEIGENE, LTD.	-19.28%	15.4B
SAREPTA THERAPEUTICS, INC.	+63.81%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.52B

Bio Therapeutic Drugs